185 related articles for article (PubMed ID: 22225675)
1. Effectiveness of type A botulinum toxins for aesthetic indications and their relative economic impact.
Jandhyala R
J Plast Reconstr Aesthet Surg; 2012 Jun; 65(6):720-31. PubMed ID: 22225675
[TBL] [Abstract][Full Text] [Related]
2. Advances in the use of botulinum neurotoxins in facial esthetics.
Flynn TC
J Cosmet Dermatol; 2012 Mar; 11(1):42-50. PubMed ID: 22360334
[TBL] [Abstract][Full Text] [Related]
3. Relative potency of incobotulinumtoxinA vs onabotulinumtoxinA a meta-analysis of key evidence.
Jandhyala R
J Drugs Dermatol; 2012 Jun; 11(6):731-6. PubMed ID: 22648220
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin: examining duration of effect in facial aesthetic applications.
Flynn TC
Am J Clin Dermatol; 2010; 11(3):183-99. PubMed ID: 20369902
[TBL] [Abstract][Full Text] [Related]
5. An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA.
Nettar KD; Yu KC; Bapna S; Boscardin J; Maas CS
Arch Facial Plast Surg; 2011; 13(6):380-6. PubMed ID: 21690460
[TBL] [Abstract][Full Text] [Related]
6. IncobotulinumtoxinA in esthetics.
Kerscher M; Yutskovskaya Y; Flynn TC
J Drugs Dermatol; 2013 Jun; 12(6):e111-20. PubMed ID: 23839200
[TBL] [Abstract][Full Text] [Related]
7. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.
Chen JJ; Dashtipour K
Pharmacotherapy; 2013 Mar; 33(3):304-18. PubMed ID: 23400888
[TBL] [Abstract][Full Text] [Related]
8. A Quantitative Analysis of OnabotulinumtoxinA, AbobotulinumtoxinA, and IncobotulinumtoxinA: A Randomized, Double-Blind, Prospective Clinical Trial of Comparative Dynamic Strain Reduction.
Wilson AJ; Chang B; Taglienti AJ; Chin BC; Chang CS; Folsom N; Percec I
Plast Reconstr Surg; 2016 May; 137(5):1424-1433. PubMed ID: 27119918
[TBL] [Abstract][Full Text] [Related]
9. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part II: Wrinkles on the middle and lower face, neck and chest.
Ascher B; Talarico S; Cassuto D; Escobar S; Hexsel D; Jaén P; Monheit GD; Rzany B; Viel M
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1285-95. PubMed ID: 20569284
[TBL] [Abstract][Full Text] [Related]
10. A two-phase, retrospective analysis evaluating efficacy of and patient satisfaction with abobotulinumtoxina used to treat dynamic facial rhytides.
Kiripolsky MG; Peterson JD; Guiha I; Goldman MP
Dermatol Surg; 2011 Oct; 37(10):1443-7. PubMed ID: 21649790
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for the best possible use of botulinum neurotoxin type a (Speywood units) for aesthetic applications.
Rzany B; Fratila AA; Fischer TC; Hilton S; Pavicic T; Rothhaar A; Sattler G; Sommer B; Pickett A
J Drugs Dermatol; 2013 Jan; 12(1):80-4. PubMed ID: 23377332
[TBL] [Abstract][Full Text] [Related]
12. Split-face double-blind study comparing the onset of action of onabotulinumtoxinA and abobotulinumtoxinA.
Yu KC; Nettar KD; Bapna S; Boscardin WJ; Maas CS
Arch Facial Plast Surg; 2012; 14(3):198-204. PubMed ID: 22183059
[TBL] [Abstract][Full Text] [Related]
13. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
Prager W; Rappl T
J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type A for aging face and aesthetic uses.
Hexsel C; Hexsel D; Porto MD; Schilling J; Siega C
Dermatol Ther; 2011; 24(1):54-61. PubMed ID: 21276158
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness and impact on quality of life of abobotulinumtoxinA and onabotulinumtoxinA in the treatment of children with lower limb spasticity in Canada.
Johnston K; Danchenko N; Hansen R; Dinet J; Liovas A; Armstrong A; Bains S; Sullivan SD
J Med Econ; 2020 Jun; 23(6):631-640. PubMed ID: 31985313
[No Abstract] [Full Text] [Related]
16. Patient Perceived Benefit in Facial Aesthetic Procedures: FACE-Q as a Tool to Study Botulinum Toxin Injection Outcomes.
Chang BL; Wilson AJ; Taglienti AJ; Chang CS; Folsom N; Percec I
Aesthet Surg J; 2016 Jul; 36(7):810-20. PubMed ID: 26780945
[TBL] [Abstract][Full Text] [Related]
17. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)--Part I: Upper facial wrinkles.
Ascher B; Talarico S; Cassuto D; Escobar S; Hexsel D; Jaén P; Monheit GD; Rzany B; Viel M
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1278-84. PubMed ID: 20337830
[TBL] [Abstract][Full Text] [Related]
18. Cost Efficiency Analysis for Spasticity Management Based on Physician Botulinum Toxin Prescribing Habits.
Kazerooni R; Howard I; Li X; Verduzco-Gutierrez M
Arch Phys Med Rehabil; 2022 Jun; 103(6):1205-1209. PubMed ID: 34852255
[TBL] [Abstract][Full Text] [Related]
19. The convergence of medicine and neurotoxins: a focus on botulinum toxin type A and its application in aesthetic medicine--a global, evidence-based botulinum toxin consensus education initiative: part I: botulinum toxin in clinical and cosmetic practice.
Carruthers A; Kane MA; Flynn TC; Huang P; Kim SD; Solish N; Kaeuper G
Dermatol Surg; 2013 Mar; 39(3 Pt 2):493-509. PubMed ID: 23458294
[TBL] [Abstract][Full Text] [Related]
20. Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population.
Kazerooni R; Watanabe JH
J Manag Care Spec Pharm; 2021 Apr; 27(4):478-487. PubMed ID: 33511895
[No Abstract] [Full Text] [Related]
[Next] [New Search]
